ArticleBreast cancer research : BCR2025

A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.

Fan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.